Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker.

R. Morgan*, R.T. Bryan, S. Javed, F. Launchbury, M.P.A. Zeegers, K.K. Cheng, N.D. James, D.M. Wallace, C.D. Hurst, D. G. Ward, M.A. Knowles, H. Pandha

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Despite significant advances in our understanding of the molecular pathology of bladder cancer, it remains a significant health problem with high morbidity and mortality associated with muscle-invasive bladder cancer (stages T2+), and high costs associated with the surveillance of non-muscle-invasive bladder cancer (NMIBC, stages Ta/T1/Tis). Moreover, current diagnostic biomarkers are suboptimal and of poor utility for low grade disease and surveillance. In this study, we show that the Engrailed-2 (EN2) transcription factor is expressed in, and secreted by, bladder cancer cell lines and patient tumour specimens, justifying an evaluation of urinary EN2 as a diagnostic biomarker in bladder cancer using archived samples from an established biospecimen collection. In patients with NMIBC, urinary EN2 was detected in most cases with an overall sensitivity of 82% and specificity of 75%. The sensitivity for stage Ta and T1 tumours was 71% and 76%, respectively, and 94% for stage T2+ tumours. This compares favourably with existing markers. The sensitivity for tumour grades 1, 2 and 3 was 69%, 78% and 87%, respectively. Thus urinary EN2 has the potential to be a more sensitive and specific protein biomarker for NMIBC than currently available tests. 

Original languageEnglish
Pages (from-to)2214-2222
Number of pages9
JournalEuropean Journal of Cancer
Volume49
Issue number9
DOIs
Publication statusPublished - Jun 2013

Keywords

  • Bladder cancer
  • EN2
  • Biomarker
  • Diagnostic
  • TRANSCRIPTION FACTOR
  • SURVEILLANCE
  • ASSOCIATION
  • PROGRESSION
  • MARKERS

Cite this